Will the Hong Kong Stock Connect innovative drugs rise or fall in the medium and long term

Sonar Pro

Vote: rise

Multiple indicators suggest Hong Kong Stock Connect innovative drugs will rise in the medium to long term. First, the index shows strong historical performance. The Hang Seng SCHK Innovative Drug Select Index (HSSCPB) has delivered +108.1% YTD returns and +100.3% over three years, significantly outperforming the broader Hang Seng Composite Index (HSCI) at +39.38% YTD[1]. Second, policy support is accelerating. China's government released measures to support high-quality development of innovative drugs in 2025, and the first Commercial Health Insurance Innovative Drug Catalog was released in December 2025, expanding payment capacity for innovative drugs[8]. Third, capital flow dynamics are strengthening. Southbound Stock Connect ADT surged to HK$121.1 billion in 2025—more than double 2024's HK$48.2 billion—with biotech and healthcare sectors concentrated in this growth[4]. The March 2026 Stock Connect adjustment is adding 14 healthcare enterprises, including innovative pharmaceutical companies, reflecting growing recognition from mainland investors[3]. Fourth, quality thresholds are rising. The inclusion threshold for Stock Connect rose to HKD 9 billion (up 26% from April 2025), ensuring mainland investors gain access to higher-quality Hong Kong biotech and pharma companies[3]. The combination of strong historical returns, supportive policy environment, surging capital inflows, and structural improvements to the Stock Connect mechanism create favorable conditions for medium to long-term gains.

GPT-5.4

Vote: rise

Medium to long term, Hong Kong Stock Connect innovative drug names are more likely to rise. The core driver is policy and capital access. Inclusion in Stock Connect expands the investor base to mainland funds, improves liquidity, and can support valuation rerating over time. Industry fundamentals also favor the sector. China’s innovative pharma companies are moving from early R&D stories to commercialization, out-licensing, and global partnerships, which makes revenues and cash flows more tangible than in earlier cycles. Valuations in many Hong Kong biotech and innovative drug stocks have already been heavily compressed after prior downturns. When a sector is priced for pessimism, even modest clinical, regulatory, or business-development success can create meaningful upside over the medium term. There will be volatility from regulation, pricing pressure, trial risk, and financing conditions. But for a diversified medium- to long-term view, improving fundamentals, broader market access, and low starting valuations make a rise the more persuasive outcome.

Grok 4.1 Fast

Vote: rise

Hong Kong Stock Connect innovative drugs, primarily biotech firms like Innovent and BeiGene, are poised for medium- to long-term growth due to China's aggressive biotech push. The 14th Five-Year Plan prioritizes innovative drugs with massive R&D subsidies, tax breaks, and accelerated NMPA approvals, fostering a pipeline of novel therapies in oncology and immunology. Aging demographics and rising healthcare spending (projected to hit 7% of GDP by 2030) create huge domestic demand, while global partnerships (e.g., with Pfizer, Eli Lilly) validate pipelines and provide revenue ramps. Valuations remain attractive (average P/E ~15x vs. US biotechs at 25x), with undervaluation amid macro noise likely to correct as earnings materialize. Recent policy relaxations for cross-border investment via Stock Connect amplify inflows from mainland capital. Risks like trial failures exist but are mitigated by diversified portfolios and historical outperformance (sector +20% annualized since 2020 listing peaks).

Kimi K2.5

Vote: rise

The medium to long-term trajectory for Hong Kong Stock Connect innovative drugs is upward due to structural demographic and policy tailwinds. China's aging population (projected to reach 400 million people over 60 by 2035) creates sustained demand for novel therapeutics, while Beijing's 'Healthy China 2030' initiative prioritizes biotech innovation over generic manufacturing. The Stock Connect mechanism itself provides a critical liquidity advantage. As Southbound trading quotas expand and dual-primary listings increase, mainland capital inflows will support valuation premiums for quality biotech assets. Many HKEX-listed innovative drug developers are approaching commercialization inflection points after years of R&D investment, suggesting revenue acceleration rather than continued cash burn. While short-term volatility exists due to regulatory pricing pressures and interest rate cycles, the 3-5 year horizon favors companies with robust pipelines and breakthrough therapies. The sector's alignment with strategic national interests—reducing dependence on foreign pharmaceuticals—provides policy insulation that generic drugs lack.

Claude Opus 4.6

Vote: rise

Several structural factors support a medium-to-long-term rise for innovative drug stocks listed on the Hong Kong Stock Connect: **Favorable Policy Tailwinds:** China has been aggressively reforming its pharmaceutical regulatory framework to encourage innovation. The NMPA accelerated approval pathways, volume-based procurement policies that punish generics but reward differentiated innovative drugs, and inclusion of novel therapies in the National Reimbursement Drug List (NRDL) all create a supportive ecosystem for innovative biotech/pharma companies. **Maturing Pipeline and Revenue Inflection:** Many Hong Kong-listed biotech companies (18A companies and others) that were pre-revenue are now reaching commercialization stages. Companies like BeiGene, Innovent Biologics, and others are generating increasing revenues from approved products and expanding their global licensing deals. This revenue inflection should drive re-rating. **Valuation Reset Creates Opportunity:** The sector experienced a severe drawdown from 2021-2023 driven by rising interest rates, geopolitical concerns, and biotech funding winter. Current valuations are near historical lows, meaning much of the downside risk is already priced in. A mean reversion alone could drive significant gains. **Global Expansion and Licensing Deals:** Chinese innovative drug companies are increasingly signing lucrative out-licensing deals with global pharma (e.g., recent multi-billion dollar deals). This validates the science, brings in non-dilutive capital, and opens global market access. **Demographic and Demand Drivers:** China's aging population and rising healthcare spending create a durable demand backdrop for innovative therapeutics, particularly in oncology, autoimmune diseases, and metabolic disorders. **Interest Rate Environment:** With global interest rates likely peaking or declining, long-duration growth assets like biotech should benefit from improved discounted cash flow valuations. While risks remain (geopolitical tensions, regulatory uncertainty, individual clinical failures), the sector-wide structural setup favors medium-to-long-term appreciation.

Gemini 3.1 Pro

Vote: rise

In the medium to long term, Hong Kong Stock Connect innovative drugs are highly likely to rise due to several strong macroeconomic and sector-specific tailwinds. First, valuations are currently highly attractive. The Hong Kong biotech sector has endured a prolonged period of steep corrections, washing out excess speculation. Many fundamentally strong companies with robust clinical pipelines are now trading at historically discounted levels, presenting an excellent entry point. Second, demographic shifts provide an undeniable structural driver. China's rapidly aging population guarantees a steadily increasing long-term demand for advanced healthcare, particularly for innovative treatments in oncology, immunology, and metabolic diseases. Third, domestic policy is highly supportive. Under initiatives like 'Healthy China 2030,' the government is actively incentivizing homegrown pharmaceutical R&D to reduce reliance on foreign drugs. Regulatory pathways have been streamlined to accelerate the approval of innovative therapeutics. Fourth, Chinese biotech firms are proving their global competitiveness. We are seeing a record number of lucrative 'out-licensing' deals where domestic companies sell the overseas rights of their innovative drugs to global pharmaceutical giants. This not only validates their R&D capabilities but also secures massive non-dilutive capital and diversifies revenue away from domestic pricing pressures. Finally, the macroeconomic environment is shifting in favor of growth stocks. As global central banks transition toward rate-cut cycles, improving liquidity and lower capital costs will disproportionately benefit capital-intensive, high-growth sectors like biotechnology.

Final Summary

The AI Roundtable reached a rare, unanimous consensus, with all six models projecting a medium-to-long-term rise for Hong Kong Stock Connect innovative drugs. The discussion was less a debate and more a layering of bullish indicators, as the group moved from Sonar Pro’s data on surging capital inflows to Claude Opus 4.6’s analysis of a fundamental 'revenue inflection point' for maturing biotech firms.

All 6 models agreed on "rise" after discussion

Strongest Arguments

• rise: The sector is transitioning from speculative R&D to commercial reality, evidenced by a record number of lucrative out-licensing deals with global pharma giants that validate the science and provide non-dilutive capital.